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Tyrosine hydroxylaseThe ever-evolving understanding of the neuronal systems involved in Parkinson's disease together with the
recent advances in recombinant viral vector technology has led to the development of several gene therapy
applications that are now entering into clinical testing phase. To date, four fundamentally different
approaches have been pursued utilizing recombinant adeno-associated virus and lentiviruses as vectors for
delivery. These strategies aim either to restore the lost brain functions by substitution of enzymes critical for
synthesis of neurotransmitters or neurotrophic factors as a means to boost the function of remaining neurons
in the diseased brain. In this review we discuss the differences in mechanism of action and describe the
scientiﬁc rationale behind the currently tested gene therapy approaches for Parkinson's disease in some
detail and pinpoint their individual unique strengths and weaknesses.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The ﬁrst reported clinical application of gene therapy was
conducted almost 20 years ago using ex vivo gene transfer by
retroviral transduction as a means to deliver functional lymphocytes
with corrected adenosine deaminase activity to a young girl with
severe combined immunodeﬁciency [1]. Although the safety of this
particular approach (and even gene therapy as a whole) was later
questioned, development of novel, non-integrating, recombinant viral
vectors and advances in the ﬁelds of immunology and virology have, aromatic acid decarboxylase;
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vivo gene delivery in several diseases that affect different tissue types
and organs. One ﬁeld where the gene therapy approach has caught
attention is the treatment of neurodegenerative disorders. As we will
detail in this review, Parkinson's disease (PD), in particular, is a well-
suited target for gene therapy for a number of reasons and not
surprisingly, there are currently four ongoing or completed clinical
trials aimed for therapeutic relief in PD utilizing viral vector-mediated
gene delivery in the brain.
The general attitude toward clinical gene therapy during the last
decade would probably be best described as careful optimism. Many
have seen it as an interesting technique for proof-of-concept studies,
but few have viewed it as a viable strategy for routine use in a broader
clinical setting. Previously, any therapy that required surgical inter-
vention was considered impractical from the points of safety,
feasibility and/or economical and human resources. The success of
deep brain stimulation (DBS) and its broad application in PD therapy
has, however, shown that such requirements are not insurmountable.
Viral vector-mediated gene transfer provides some unique advan-
tages that can make it preferable over traditional pharmacotherapy in
neurological disorders. A number of traits of PD illustrates this
distinction well: Firstly, gene therapy enables delivery of complex
molecules or enzymes to speciﬁc regions of the brain at constant rates.
This provides an opportunity to explore novelmechanisms for therapy
and modulation of individual pathways. The bio-distribution of the
virally expressed therapeutic protein can be optimized speciﬁcally for
each patient by controlling the placement of injection, volume and
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of adverse effects otherwise linked to the same therapeutic approach,
when applied systemically. In many neurological disorders, neuronal
populations located in different nuclei in the brain are effected to
varying extent. A systemically delivered drug might therefore normal-
ize the system in some regions of the brain but at the same time over-
stimulate other neurons of the same kind in regions less affected by
the disease process.
Secondly, the socioeconomic aspects of gene therapy based
medications could be generally more favorable than might be
assumed. The increase in life expectancy and reduced birth rate
seen in most countries of the industrialized world during the last
decades has resulted in a rapid increase in the aged fraction of the
population. Therefore, governments face dramatic increases in
healthcare costs due to age-related diseases. One of the categories
that put signiﬁcant strain on the budget is debilitating, chronic
diseases that effect people at working age such as PD, which exhibits
an average onset age of 58 years in the US.With only a slight reduction
in life expectancy due to the disease [2], most patients would require
therapy for at least 20 years and as 5–10% of them develop symptoms
before the age of 50, it can in many cases be signiﬁcantly more. While
the introduction of novel compounds such as long lasting dopamine
(DA) agonists and various enzyme inhibitors into the routine arsenal
of medication might have improved the duration of good response to
pharmacotherapy, the costs of treatment per patient and year have
increased substantially. Gene therapy treatments, on the other hand,
are based on a single intervention principle, resulting in stable and
long-term (maybe life-long) expression of the therapeutic molecule in
the brain. Reduction in the requirement for medication in turn might
reduce the ﬁnancial burden of the treatment to society.
Thus far, three clinical trials targeting PD patients have been
completed and published as peer reviewed scientiﬁc papers [3–6]. All
three studies were conducted using recombinant adeno-associated
virus serotype 2 (rAAV2) vectors with the transgene expressed under
a ubiquitous promoter. Furthermore, all three studies aimed to test the
safety, tolerability, and preliminary efﬁcacy of the proposed strategy in
an open-label, phase I clinical trial design. The tested therapeutic
molecules and the principle mechanism of action, however, vary
greatly between them.
In this review, we aim to describe in detail the current clinical
approaches for gene therapy in PD (where information is available),
the rationale and pre-clinical evidence for the chosen paths. We have
chosen not to cover the choice of viral vectors for the experimental
and clinical applications here as this topic has been reviewed detailed
elsewhere [7,8].
2. Principles and the rationale for the strategies tested in the
ﬁrst gene therapy trials in Parkinson's disease
The molecular pathways and target structures in the recently
published clinical trials were chosen based a number of pre-clinical
and clinical observations, some of which are well supported, whereas
others, in our opinion, are not sufﬁciently documented. Based on their
functional target and mechanism of action these trials can be
reviewed under three categories: (1) restoration of DA synthesis in
the dorsal striatum; (2) modulation of activity in the basal ganglia
downstream of the striatum; and (3) modiﬁcation of disease
progression by neuroprotection.
2.1. Restoration of DA synthesis capacity
Since the discovery of DA as a neurotransmitter and its involve-
ment in Parkinson's disease [9–12], the focus of pharmacological
therapies has been on restoring the DAergic tone in the brain. The
reconstitution of striatal DA via peripheral L-DOPA (3,-dihydroxyphe-
nylalanine), combined with peripheral decarboxylase inhibitors, hasproven itself as one of the most successful therapies for a neurological
disorder [13] and became the gold-standard for PD pharmacotherapy
[14,15]. In the initial years, when motor complications are the
predominant symptoms of the disease, L-DOPA medication provides
excellent symptomatic relief and can greatly improve the quality of
life for the patient. However, long-term treatment with L-DOPA is not
without limitations and adverse events, which inevitably emerge in
more than 80% of all PD patients within the ﬁrst 10 years from disease
onset [16]. With disease progression non-dopaminergic neural
systems become affected, which cannot be effectively alleviated
with L-DOPA. In addition, some patients may show signs of
involuntary movements, so-called dyskinesias, already in the ﬁrst
few years. Furthermore, L-DOPA can lead to other adverse events can
include for instance hypotension, sexual dysfunction or psychiatric
side effects [17,18].
Pharmacokinetics and bio-distribution studies suggest large
ﬂuctuations in the serum levels of L-DOPA after oral administration
[19,20]. Thus, it was hypothesized that the development of dyskinesias
might be a result of the ﬂuctuations in DA concentrations at the
synaptic sites in the denervated striatum. This hypothesis is supported
by clinical data showing that continuous infusion of L-DOPA, delivered
either intravenously or via duodenal pump can signiﬁcantly reduce
the occurrence and magnitude of dyskinesias and decrease the daily
“off” time [21–23]. Similar results have been reported with intrave-
nous and duodenal infusion of apomorphine, a non-selective DA
receptor agonist [24]. Continuous DA stimulation using L-DOPA
infusion pumps or DA receptor agonists is a valuable addition to the
plethora of alternatives used to control “on–off” ﬂuctuations and
dyskinesias in late stage patients. However, these approaches do not
address and in some cases worsen several of the complications. First,
systemically delivered DAergic drugs reach the whole brain at high
concentration. This is clearly not the best approach since not all brain
regions suffer from DAergic degeneration to the same extent. For
example, the requirement of additional DAergic tone might be
substantially less in the limbic and cortical areas than the severely
affected striatum. Thus, in this mode of treatment these regions might
be constantly over-stimulated with high DA tone, which is adjusted
primarily for relief of motor symptoms in the patients. Therefore,
other treatment approaches that can locally enhance the DA
concentrations in the striatum could prove to be more beneﬁcial
and limit the occurrence and severity of side effects to levels not
achievable with the currently available treatment modalities.
At least three major gene therapy strategies have been developed
to synthesize DA locally in the brain (graphically represented in Fig.1).
The main factor that differs between these approaches is the
interpretation of which enzymes are necessary and sufﬁcient to
express ectopically in the target area of the brain to reconstitute the
DA synthesis capacity. It is widely accepted that the Tyrosine
hydroxylase (TH) enzyme activity is signiﬁcantly reduced in the
parkinsonian striatum, severely compromising the rate of synthesis of
DOPA from tyrosine. Thus, it is clear that striatal DOPA must be
replaced.Whether the amount of aromatic acid decarboxylase (AADC)
enzyme available in the diseased brain is sufﬁcient for synthesis of DA
in the appropriate target regions, however, is a matter of debate. The
AADC enzyme is present in the striatum, not only in DAergic axons but
also in serotonergic terminals [25,26], but it has been shown that the
levels are decreased in the striatum of PD patients. The reported level
of residual AADC activity is variable between patients and also
between studies. It could be as low as 5% in the most severely affected
cases, and usually larger decreases are found in the putamen than the
caudate nucleus [27,28].
2.2. Pro-drug approach for enhanced DA synthesis
If the levels of AADC enzyme were increased or even restored to
normal levels selectively in the striatum, then a larger fraction of the
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brain. As a result, the dose of oral L-DOPA could be decreased with
maintained efﬁcacy, whereas the effects due to extra-striatal DA
synthesis may be minimized. This strategy is also known as the pro-
drug approach. The ﬁrst proof-of-principle for this therapy was
demonstrated in primates with a unilateral MPTP (1-methyl 4-
phenyl 1,2,3,6-tetrahydropyridine) lesion that received an injection
of rAAV2 vectors coding for the human AADC gene. These animals
showed increased conversion efﬁcacy of peripheral L-DOPA to DA as
seen by biochemical analysis of tissue punches from the transduced
striatum [29].
When applied to MPTP lesioned non-human primates, rAAV
mediated AADC delivery resulted in an increased accumulation of
[18F]-MT (ﬂuoro-L-m-tyrosine), in the transduced striatum compared
to lesion controls [29]. FMT is an L-DOPA analog that cannot be
methylated by catechol-O-methyltransferase (COMT) in peripheral
organs and erythrocytes but is still a valid substrate for the AADC
enzyme. Thus, the background signal in the brain is less then that of
[18F]-DOPA but with maintained speciﬁcity for neurons that display
decarboxylase activity [30]. [18F]-MT retention in the brain correlates
well with the total concentration of AADC (present in dopamine,
serotonin and norepinephrine containing neurons) but is not
dependent on vesicular monoamine transporter (VMAT2) function
[30]. In a follow-up study, Bankiewicz and colleagues presented long-
term behavioral improvement and in vivo AADC enzyme activity for
up to 6 years after rAAV-AADC transduction of MPTP treated
monkeys [31]. The animals displayed a 50% improvement in the
clinical rating scale after a single injection of L-DOPA at a dose that
was not sufﬁcient to induce a signiﬁcant improvement in control
vector injected animals. However the duration of action for
peripheral L-DOPA in these rAAV-AADC transduced primates was
not reported. Nevertheless, the behavioral effects were coupled with
a normalized striatal [18F]-MT uptake that was stable for the full
duration of the study [31].
The pro-drug approach is often touted as attractive from a safety
point of view because it enables peripheral regulation. In case of
adverse events, the peripheral supply of L-DOPA can be discontinued
and the ectopic AADC enzyme would be rendered inactive. However,
one point of concern is if the ectopic release of DA from transduced
cells were too efﬁcient, the extracellular levels of DA after an oral L-
DOPA intake might increase too rapidly. Thus the therapy could
increase the ﬂuctuations of DA supply and aggravate dyskinesias. In
fact, it has been shown in primates that even AADC over-expression
alone can potentiate L-DOPA-induced dyskinesias if the transduction
is heterogeneous [32]. If this were to happen, the daily L-DOPA dose
would have to be decreased or even discontinued until the adverse
events disappear. However, as oral L-DOPA is the main, most
efﬁcacious pharmacotherapy for the patients, this would leave them
worse off than before the intervention.Fig. 1. Schematic drawings of viral vector-mediated enzyme replacement strategies in
the parkinsonian brain. (A) Pro-drug approach for enhanced DA synthesis. rAAV
mediated gene transfer of AADC results in expression of the enzyme at high levels in
striatal neurons from an episomal plasmid. L-DOPA from oral pharmacotherapy enters
the brain over the blood–brain barrier. It is taken up by the transduced striatal neuron
and converted by the ectopic AADC to DA that probably accumulates in the cytoplasm
and diffuses towards the post-synaptic DA receptors providing symptomatic relief. (B)
Dopamine replacement. The multi-cistronic EIAV vector infects the striatal neuron
where the genes are integrated in the host genome. As the vector carries all three genes
required for DA synthesis (TH, GCH1 and AADC), dietary tyrosine can be used to
synthesize DA within the striatal neuron at a constant rate. This DA then exits the
neuron and reaches the DA receptors in the same way as in panel A. (C) Continuous
DOPA delivery strategy. rAAV mediated gene transfer of TH and GCH1 results in
transduced striatal neurons that can synthesize DOPA form dietary Tyrosine at a
constant rate. However, as the cells do not possess the decarboxylase activity, the DOPA
exits the cell and ends up in spared DA ﬁbers or Serotonergic terminals. There it is
converted by endogenous AADC enzyme into DA and stored in vesicles by the VMAT2
transporter. The ectopically derived DA (in blue) therefore competes with endogenous
5-HT or DA (in red) for storage and release.
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of AADC as a therapy for PD is currently ongoing. In this study, ten
patients with advanced PD (Hoehn and Yahr Stage III to IV) were
injected bilaterally into the postcommisural putamen with an rAAV2-
AADC vector (ClinicalTrials.gov registry number NCT00229736). The
ﬁrst group of ﬁve patients has been operated to date. These patients
received 9×1010 vector genomes (vg) of the rAAV2-AADC vector and
were followed for 6 months post injection with evaluation using both
the Uniﬁed Parkinson's Disease Rating Scale (UPDRS) and Positron
Emission Tomography (PET) imaging utilizing [18F]-MT. The treatment
was well tolerated and induced a robust increase in [18F]-MT uptake
6 months post injection. The patients, however, did not display any
improvement in UPDRS “on” score i.e. on oral L-DOPA medication but
improved off medication [4]. These results were somewhat contrary to
the assumed function as the over-expressed AADC was expected to
mediate its functional effects via enhanced conversion of peripheral L-
DOPA to DA.
2.3. Dopamine replacement
The alternative to the pro-drug approach is to reconstitute all
the enzymes that are required for DA synthesis in the parkinsonian
striatum. In the normal brain, the DOPA substrate used by the AADC
enzyme to synthesize DA is generated from dietary tyrosine by the
TH enzyme. This enzymatic conversion is very inefﬁcient in the
absence of the co-factor tetrahydrobiopterin (BH4) [33–35]. As a
large fraction of the striatal BH4 content is lost with DA
denervation, the availability of this co-factor limits the efﬁcacy of
the DOPA synthesis from ectopically expressed TH [36,37]. The rate-
limiting enzyme in the production of BH4 is the conversion of GTP
to dihydroneopterin triphosphate by the GTP cyclohydrolase 1
(GCH1) enzyme. Further conversion of this intermediate to BH4 is
then catalyzed by two ubiquitously expressed enzymes, 6-pyruvoyl-
tetrahydropterin synthase, and sepiapterin reductase. Therefore, co-
transduction of TH and GCH1 genes is sufﬁcient to sustain high
levels of DOPA synthesis in various cell-types both in vitro and in
vivo (see [8] for a detailed review of this topic). These two enzymes
can then be combined with AADC to provide a 3-enzyme
replacement strategy for direct synthesis of DA in the transduced
cell in the brain. Shen and colleagues demonstrated that in vivo
gene transfer using a mixture of three rAAV vectors coding for TH,
GCH1 or AADC can induce DA synthesis in the DA denervated
rodent striatum and that this ectopic DA can reduce apomorphine
induced rotation by up to 80% for at least 12 months [38]. The same
mixture of rAAV vectors were later applied to parkinsonian
cynomolgus monkeys where the animals were reported to improve
by up to 64% in the Primate Parkinsonian Rating Scale (PPRS) at
2 weeks post transduction and remained stable throughout the
study up to 10 months [39,40].
EctopicDAproduction in striatal cells, however, raises concerns due
to the fact that the DA synthesis is localized to cells that have no
vesicular storage and release mechanism for this neurotransmitter
(Fig. 1B). The ﬁrst problem that needs to be resolved in this scenario is
the strong negative feedback of free cytosolic DA on the TH enzyme
both by forming an inhibitory complex with ferric iron (Fe3+) and
by competitive inhibition of the BH4 substrate binding within the
active site of the enzyme (reviewed in detail by Kumer and Vrana
[41]). This limitation was demonstrated by Kang and collaborators in
an experiment comparing primary ﬁbroblasts, transduced either
with GCH1 and TH, AADC alone or a combination of all three genes
[42]. DA synthesis, both in vitro and in the denervated rodent
striatum, was signiﬁcantly reduced when the primary ﬁbroblasts
expressed decarboxylase activity in the same cell as the TH activity
compared to a setting where these two functions were separated
into different cell populations. The inhibition of the TH enzyme can
be alleviated by phosphorylation of Serine 40 by reducing the Km forthe BH4 co-factor and increasing the inhibitory constant (Ki) of DA
[43]. It is also known that the enzymatic properties remain and are
even slightly enhanced after digestion of the ﬁrst 158 amino acids of
the TH enzyme [44,45] Thus, the truncated form of the TH enzyme
(tTH) that lack the regulatory N-terminal fragment becomes
constitutively active regardless of cytosolic DA possibly due to
decreased negative feedback [46].
The equine infectious anemia virus (EIAV) was used as a vector
platform to carry a tricistronic construct encoding for tTH in
combination with the GCH1 and AADC genes[47]. Injection of this
multi-cistronic vector into the striatum of hemiparkinsonian rats
resulted in a partial decrease in apomorphine induced rotation but did
not result in any detectable increase in striatal DA levels. These results
were considered as sufﬁcient basis for a continued development of
this vector as a product for clinical testing (ProSavin, Oxford
Biomedica, UK). In follow-up studies performed by Oxford Biomedica,
the ProSavin vector was injected into MPTP lesioned primates. The
company reported in a press release that, at repeated time-points up
to 15 months after the vector injection, the monkeys improved their
motor performance signiﬁcantly [48]. With these results, a phase I/II
clinical trial has now been initiated in patients with PD [49].
Elevated cytosolic DA levels has been hypothesized to play a critical
role in nigral degeneration in PD [50]. Therefore, uncontrolled DA
synthesis in cells that lack storage and release mechanisms raises
concerns for the long-term implication of ectopic DA accumulation. In
fact a recent study in a transgenic mouse model where the DA
transporter, DAT, was ectopically expressed in the forebrain cells
illustrated this very nicely [51]. The net effect in this model system is
that DA released from the pre-synaptic DAergic neuron can be
internalized, not only by pre-synaptic terminals (normal re-uptake
mechanism) but also by post-synaptic cells in the striatum. As the
striatal neuron lacks storage and releasemechanisms, DA accumulates
in the cytoplasm of these cells resulting in severe oxidative stress,
leading to neuronal loss and premature lethality.
2.4. Continuous DOPA delivery strategy
An alternative approach to viral mediated DA delivery is the
continuous DOPA delivery strategy. Although those two concepts
might, on the surface, seem like variations on the same theme, they
differ signiﬁcantly on a number of important points. Continuous
DOPA delivery using viral vector-mediated gene transfer relies on
endogenous AADC activity for synthesis of DA locally in the brain.
Two major sources of AADC in the striatum are the DA and
serotonin (5HT) terminals. Thus in the parkinsonian brain the
remaining DA axons and the serotonergic terminals are the two
most likely places where for conversion to (and release of) DA
takes place. As the disease progress, it is anticipated that fewer and
fewer DA terminals will remain. Nevertheless, the serotonergic
denervation of the striatum is signiﬁcantly less than the DAergic
one in PD patients and thus it may remain as a reliable long-term
source in majority of the patients [52]. By separating the L-DOPA
synthesis (taking place in transduced striatal neurons) and DA
synthesis and release (taking place in DA and 5HT terminals), a
number of the afore-mentioned potential complications can be
avoided (Fig. 1C) i.e., the need for expression of a constitutively
active truncated TH enzyme and the risks associated with
intracytoplasmic accumulation of DA in striatal GABA (gamma-
aminobutyric acid) neurons.
The initial studies in this area were instrumental in establishing
that not only TH but also BH4 (or the GCH1 gene) had to be provided
for optimal DOPA synthesis in the parkinsonian brain. In the ﬁrst
study Corti et al. used recombinant Adenoviral (rAd) vectors to
deliver the TH gene. When the animals were injected systemically
with high levels of BH4, a 10–15 fold increase was detected in DOPA
levels in the striatal tissue of the rAd-TH treated rats [53]. In a second
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GCH1 was shown to be comparable to that of animals receiving the
single rAAV2-TH vector combined with reverse microdialysis that
delivered BH4 directly to striatal neurons [54]. The combined rAAV2-
TH and rAAV2-GCH1 strategy was explored further by utilizing a new
generation of rAAV2 vectors where therapeutic levels of DOPA
synthesis could be reached. At these levels of continuous DOPA
synthesis, the animals did not only recover in drug-induced rotation
tests but also showed improvements on a spontaneous motor test
[55]. Notably, the magnitude of improvements were greater in
animals with spared partial striatal DA innervation (in the order of
10–20% of normal) compared to animals with complete DA lesions
(with b5% residual innervation), suggesting that the remaining DA
terminals played an important role in mediating the therapeutic
effects following the ectopic DOPA synthesis [55]. In line with latter
data, Carlsson and colleagues recently showed that rAAV5-mediated
DOPA delivery could reverse previously manifested L-DOPA-induced
dyskinesias in rats [56]. In this study, rats with intrastriatal 6-
hydroxydopamine (6-OHDA) lesion with moderate-to-severe beha-
vioral impairments received daily pulsatile L-DOPA treatment until
they were rendered stably dyskinetic. After striatal injection of
rAAV5-TH and rAAV5-GCH1, the severity of the abnormal dyski-
netic movements gradually decreased to about 15% of the initial
scores at 12 weeks post injection [56].
We have recently complemented these encouraging results with
proof that DA synthesized after this gene therapy approach reaches
the post-synaptic receptors on striatal neurons in a physiological
manner and that the therapeutic effects are correlated with
normalization of the DA [57]. The study utilized the [11C]-raclopride
as a PET tracer to monitor the occupancy of the striatal DA receptors
where the binding afﬁnity (Kd) and the apparent maximum binding
potential (B′max) could be quantitatively measured in a single
imaging session. We found that complete DA lesion resulted in a
decrease in Kd but did not affect the B′max. Importantly, the change
in Kd could be reversed by the rAAV mediated continuous DOPA
delivery, indicating that the ectopically synthesized DOPA was
converted to DA and that it was biologically active in a physiological
way at the DA synapses in the striatum [57].
Taken together, these data show that viral vector-mediated,
continuous DOPA delivery is an attractive strategy for enzyme
replacement in PD and should be pursued further with the ultimate
goal being clinically tested for efﬁcacy.
3. Modulation of basal ganglia circuitry
Neurosurgical intervention to reduce motor complications in PD
has a long history and was the treatment of choice before the
introduction of L-DOPA pharmacotherapy. In fact, already in 1947, the
article reporting the ﬁrst stereotactic surgery of the human brain
described its application to modulate involuntary movements in
patients [58]. A couple of years later, lesion of the medial nucleus of
the thalamus (thalamotomy) was shown to be effective on treating
tremor [59]. During a quest for reﬁned lesioning paradigms, it was
found that lesions to the globus pallidus (pallidotomy) did not only
have a positive effect on the tremor in patients with PD but also
reduced ﬂuctuations and dystonia [59,60].
However, surgical lesions in the brain are irreversible and the
effects difﬁcult to predict. Thus, novel methods for site-speciﬁc
inhibition of deep brain nuclei were explored. The most efﬁcient
solution was found to be an electrode, connected to a high frequency
neurostimulator. This was ﬁrst applied to the thalamus and was found
to have a lower rate of complications than thalamotomy [61]. The
mechanism of action for this intervention is not fully understood yet,
but is thought to be via inhibition of neurons by depolarization in the
volume inﬂuenced by the electrical probe. This technique is now,
somewhat inaccurately, named DBS. It was later found to be efﬁcientin other functional domains of the basal ganglia as well. Especially the
internal segment of the globus pallidus (GPi) and the subthalamic
nucleus (STN) gained much attention [60,62]. The beneﬁts of DBS in
the STN in patients with PD include improvements in akinesia, rigidity
and tremor to such extent that L-DOPA pharmacotherapy can be
reduced which is also coupled with a reduction in L-DOPA-induced
dyskinesias [63].
3.1. Targeting STN using viral vectors for functional recovery in PD
The success of the DBS encouraged During and collaborators to
use a molecular mechanism to inhibit the hyperactive glutamatergic
drive originating from the STN in PD patients via gene therapy [64].
The enzymatic synthesis pathways for the excitatory glutamate
(Glu) and the inhibitory GABA have many similarities. In fact, GABA
is synthesized directly from Glu by the glutamic acid decarboxylase
(GAD) enzyme. Thus, over-expression of GAD in a glutamatergic
neuron should lead to synthesis of GABA instead. Intriguingly, the
vesicular transporter for Glu is highly speciﬁc and will not store
GABA in vesicles [65,66], therefore the storage and release of the
pseudo-transmitter in the transduced cells is probably compro-
mised. The initial experiments were conducted in intact and 6-
OHDA lesioned rats, which received injections of rAAV2 vectors
coding for GAD65 and GAD67 or the Green Fluorescent Protein
(GFP) marker gene into the STN [67]. In these animals, GABA release
was measured after activation of STN in the substantia nigra pars
reticulata (SNr), a region innervated by neurons originating in the
STN, which are normally glutamatergic. rAAV2 mediated over-
expression of GAD65 lead to an increase in releasable GABA that
was coupled to a decrease in amphetamine induced rotation and
motor asymmetry in this unilateral lesion model. This study was
later replicated in MPTP treated rhesus monkeys that received a
unilateral injection of either rAAV2-GAD (mix of two vectors
expressing either GAD 65 or GAD67) or rAAV2-GFP. As both the
MPTP lesion and therapeutic manipulation was unilateral, the study
focused on imaging outcomes and showed an increased metabolism
in the ipsilateral motor cortex of the animals that ectopically
expressed GAD enzymes compared to the control vector injected
animals as assessed by [18F]-deoxyglucose ([18F]-DG) PET. There
were no signiﬁcant differences between the groups in behavioral
scores obtained using the clinical rating scale [6].
The ﬁrst clinical trial utilizing viral vector-mediated gene transfer
in PD was conducted using this therapeutic strategy. An rAAV2
vectors coding for GAD65 and GAD 67 were infused unilaterally into
the STN of twelve PD patients with UPDRS score of 30 or more in
“off” state and/or complications of L-DOPA pharmacotherapy
(ClinicalTrials.gov registry number NCT00195143). The outcome of
this safety trial was positive with no dropouts or patients lost to
follow-up and no adverse events related to the gene therapy were
reported [6]. The patients displayed improvements in motor UPDRS
scores relative to baseline disability scores prior to gene therapy,
predominantly on the side of the body that was contralateral to the
treated side. The effect was seen ﬁrst at 3 months after surgery and
persisted up to 12 months when the report was published.
This clinical trial also utilized a novel imaging protocol that
analyzed deviations from normal brain function and quantiﬁed
restoration as therapeutic efﬁcacy by measuring the modiﬁed cellular
metabolism through imaging using [18F]-DG PET and a complex
analysis of linked changes in spatially distributed neural networks
with related functions. With this approach, abnormal disease-related
covariance pattern (PDRP) can be linked to motor manifestations of PD
that differ from a PD-related cognitive pattern (PDCP) [68,69]. In the
rAAV2-GAD treated patients a signiﬁcant reduction in thalamic
metabolism and an associated increase in ipsilateral motor cortex
metabolismwas found at 12 months [5]. Based on these data, a phase II
randomized, multi-center, double blind, placebo control, safety/
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Trials.gov registry number NCT00643890).
4. Disease modifying strategies
As PD is a progressive neurodegenerative disorder that affects
some neuronal populations rather selectively, there has been an
intense effort to ﬁnd disease-modifying strategies to slow down or
reverse the degenerative process. Although the patients would have
typically lost about 50% of their nigral DA neurons and about 60–80%
of striatal DA at the time of clinical diagnosis [63,70,71], the residual
DAergic neurons constitute a signiﬁcant substrate, onwhich therapies
aiming at neuroprotection and repair might yield potent recovery
from disease symptoms.
The glial derived neurotrophic factor (GDNF) was discovered in
1993 and has become the most studied molecule in the pursuit of
neuroprotection in PD [72–74]. As a member of the transforming
growth factor-β family, which also includes neurturin (NTN),
neublastin/artemin and persephin, GDNF was ﬁrst discovered in an
in vitro assay because of its potent neurotrophic activity on the
survival of midbrain DAergic neurons [74]. GDNF is expressed at high
levels in the striatum during development and is maintained at low
levels into adulthood. Knockout mouse models have severe deﬁciency
in kidney development that lead to premature death of the animals
[75]. In addition, GDNF expression in the adult intact or parkinsonian
brain was found to be below detection limit [76]. Thus, initially the
precise role of GDNF in the maintenance of DA neurons was not
possible to demonstrate. More recently, however, a conditional
knockout mouse model was utilized, where the GDNF expression
was turned off in the adult mouse, leading to an about 60% reduction
in nigral GDNF levels. This was sufﬁcient to cause a more than 50% loss
of nigral DA neurons within 7 months, supporting the view that GDNF
was essential in the maintenance of the DA neurons in the adult life
[77,78].
The in vivo neuroprotective potential of GDNF has been studied
in detail by administration of the puriﬁed recombinant protein
either into intracerebroventricular (ICV) space or into the brain
parenchyma. These studies showed good neuroprotective effect
from single or repeated injections of GDNF or continuous infusion
using pumps in both the rodent and primate models of PD [79–83].
Although an extensive review of the data is beyond the scope of the
present paper, it is sufﬁcient to say that the magnitude of the
neuroprotective effect seen after GDNF administration is critically
dependent on the site of delivery, time and duration of treatment, as
well as the mechanism of action the model employs to generate the
DAergic lesion [80,84–87].
4.1. GDNF infusion trials
The ﬁrst clinical trial testing the efﬁcacy of GDNF in PD patients
was initiated already in 1996, a mere 3 years after the discovery of
the molecule. Fifty subjects with moderate or advanced idiopathic PD
were chosen for the study and received infusion of recombinant
GDNF protein into the ICV space using mechanical pumps [88]. The
study was conducted in a double blind manner and the patients on
the active arm received single monthly bolus injections of 25–
4000 μg GDNF into the lateral ventricle over 28 months, although
only the ﬁrst 8 months of the trial was blinded. The results showed
not only that the patients did not improve in response to GDNF but
also a number of side effects of the medication were observed [88].
These adverse events have in hindsight been attributed to GDNF
stimulation of extra-striatal brain regions and the lack of therapeutic
efﬁcacy was thought to be due to the limited penetration of GDNF
from the cerebrospinal ﬂuid into the brain parenchyma. The latter
was clearly demonstrated by post-mortem analysis in one of the
patients from the study [89].The failure of the ﬁrst clinical study elucidated the need for
alternative delivery paradigms that could achieve delivery at the
expected site of action, i.e., in the putamen. In two subsequent open-
labeled clinical trials, L-DOPA responsive idiopathic PD patients
received GDNF infusion via an intraparenchymal catheter bilaterally
into the postero-dorsal putamen [90,91]. This time the results were
more encouraging as both trials met the primary endpoint with no
serious adverse events. Furthermore, the patients experienced
measurable beneﬁts in motor function with 40% improvement in the
motor sub-score of UPDRS at the one-year time point. In post-mortem
histological examination of one patient, who died almost four years
after onset of GDNF treatment, dense TH-immunoreactivity was found
around the injection tract, probably due to sprouting of nigrostriatal
ﬁbers [92].
Based on these data, a multi-center, blinded, clinical trial testing
the efﬁcacy of intraputaminal recombinant GDNF protein infusion
was initiated [93]. The results from this trial failed to conﬁrm the
preliminary observations of therapeutic efﬁcacy reported in the
open-label trials. Some patients displayed adverse events due to
the GDNF infusion, including paraesthesias and headache. Although
there was an increase in [18F]-DOPA uptake around the infusion
cannula in the posterior putamen of the treated patients, they
actually displayed a tendency towards a worsening of the UPDRS
scores. The discrepancies between the open-label and blinded GDNF
trials remain unclear, but differences in surgical protocols, selection
of the patients in the trial, the infusion protocols and possible
placebo effects have all been suggested to have contributed to the
different outcomes between the previous open-labeled trials and the
latter phase 2 trial [94].
4.2. Viral vector-mediated delivery of neurotrophic factors
Infusion of recombinant protein using intraparenchymal cathe-
ters was a good tool for proof-of-concept studies, however, for long-
term, continuous delivery of GDNF other techniques had to be
developed. Among those described in the literature, thus far, viral
vector-mediated gene transfer is undoubtedly the most powerful
technique for this purpose. The ﬁrst studies using this approach
utilized a recombinant adenoviral vector to deliver the GDNF gene
to the host brain. Injection into the rat SN prior to the 6-OHDA
lesion showed that GDNF locally synthesized in the brain was able
to protect DA neurons from the toxic insult [95]. However, the
rescue of nigral neurons was not coupled to protection of striatal DA
innervation and thus whether neuroprotection in the SN could be
linked to functional rescue remained elusive. It was later found that
both nigral and striatal injection delivery of GDNF resulted in
protection of nigral DA neurons but only striatal GDNF over-
expression was capable of sparing the DA ﬁbers and decreasing
the extent of the lesion [96]. First generation rAd vectors used in the
initial studies were not ideal for in vivo gene delivery, neither in
experimental settings nor in clinical applications, because they
induced a severe inﬂammatory response in the brain. Thus, most of
the studies aiming at gene therapy for GDNF, employed other
recombinant viral vectors with better safety and efﬁcacy proﬁle, e.g.,
rAAV and lentiviral (rLV) vectors [97,98]. (See [80,87,99–100] for in
depth reviews of the topic.)
In studies using viral vectors to deliver GDNF, a number of
important observations have been made: First, GDNF expressed in the
striatum after gene transfer resulted in robust protein synthesis in the
host brain. The GDNF molecule diffused very well within the brain
parenchyma and was biologically active even at very low expression
levels (representing only 2–3 fold increase over basal levels) [101].
The capacity to reach large areas in the target structurewas in contrast
to the outcome of the clinical trials utilizing protein infusion where
poor tissue penetration was suggested to be one of the main reasons
for the lack of efﬁcacy [89,93].
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intense sprouting of DA ﬁbers when present in the host brain at the
time of lesion [96,102]. This might prove to be beneﬁcial but may also
be a reason for concern. On the one hand, if the sprouting occurs
within the partially denervated striatum, the increased terminal
density might compensate for the lost DA neurons and induce
behavioral recovery or improved handling of peripheral L-DOPA.
Ectopic sprouting e.g., in the globus pallidus (GP) or the SNr, on the
other hand, might be less beneﬁcial or even detrimental. Sprouting in
the GP has been seen after striatal infusion of GDNF protein as well
[103], but was more intense after viral vector-mediated GDNF gene
transfer studies [101,104–106]. This effect might be due to the
efﬁcient anterograde transport of the protein in the transduced
striatal neurons projecting to this region.
4.3. Neurturin gene therapy
NTN was discovered in 1996, as the second member of the GDNF
family of neurotrophic factors [107]. It was soon found to promote
survival of midbrain DA neurons both in vitro and in vivo [108,109].
NTN and GDNF share 42% sequence homology and both mediate
action via formation of a receptor complex consisting of the tyrosine
kinase RET [110] and a ligand-binding glycosyl-phos-phatidylinositol
(GPI)-linked subunit (GFRα). They differ in their afﬁnity to bind GFRα
subunits, GDNF preferentially binds to GFRα1, whereas NTN binds to
GFRα2 (See [86] for a review of this subject). Nevertheless, NTN has
been found to bind and promote action via GFRα1 as well albeit at
lower afﬁnity [110].
Intraparenchymal delivery of recombinant NTN protein provided
neuroprotective activity at about the same magnitude as GDNF in
models of PD [111–113]. However, viral vector-mediated expression of
NTN resulted in low synthesis and poor neuroprotective efﬁcacy in
vivo. When synthesized in neurons, NTN is insufﬁciently processed
and secreted as pro-NTN. Pro-NTN does not form signaling complexes
with the Ret tyrosine kinase receptor and GFRα1 or GFRα2 and thus it
does not have any biological activity [114]. By exchanging the signaling
peptide to immunoglobulin heavy-chain signal peptide (IgSP) [114],
or the pre-pro domain of nerve growth factor (NGF) [115], the
secretion properties and biological activity of ectopically synthesized
NTN could be regained. When these modiﬁed forms of NTN were
delivered into the brain using rLV or rAAV2 vectors, the neuroprotec-
tive effects were very similar to GDNF with protection of midbrain
neurons from striatal 6-OHDA lesion in the rat or intracarotid MPTP
injection in the primate brain [114,115].
In preparation for clinical trials, rAAV2-NTN was evaluated in the
non-human primate MPTP model of PD, in aged primates and in 6-
OHDA lesioned rats at a broad range of expression levels to show long-
term efﬁcacy and safety ([116–119].
In the ﬁrst (phase I) trial, twelve PD patients received bilateral
injection of rAAV2-NTN into the pre- and postcommisural putamen.
(ClinicalTrials.gov registry number NCT00252850) [3]. The study was
conducted in a dose-escalation design with the ﬁrst six patients
receiving 1.3×1011 vg of rAAV2-NTN and a second group of six
patients a 4-fold higher dose. All patients received a total of 80 μl of
viral vector suspension stereotactically infused along four injection
tracts and 2 deposits per track in each putamen, resulting in a total of
16 deposits. Theywere monitored for 12months with extensive safety
monitoring. The procedure was well tolerated, and the patients
revealed no clinically signiﬁcant adverse events at that timepoint [3].
The efﬁcacy of the therapy was assessed as a secondary endpoint. In
several measures of motor function, the patients showed improve-
ment at 1 year; e.g., a mean improvement of 14 points in the off-
medication motor sub-score of the UPDRS (36% mean increase) and a
mean increase of 2.3 h (25% group mean increase) in on time without
troublesome dyskinesia. Interestingly, both doses of the vector
resulted in similar improvements. Non-motor symptoms were notsigniﬁcantly affected, nor were there any changes in [18F]-DOPA
uptake as assessed by PET imaging.
The follow-up study was designed as a double blind, multi-center
phase II study testing the efﬁcacy of rAAV2-NTN to reduce UPDRS
motor “off” scores in PD patients (ClinicalTrials.gov registry number
NCT00400634). This study included 58 PD patients with advanced
disease. Two thirds of the patients were recruited to the active arm
that received intraputaminal rAAV2-NTN injections and the remaining
third of the subjects were followed as placebo controls. Ceregene has
recently announced that the study failed to reach its primary endpoint
[120]. There were no signiﬁcant differences between the active
treatment and control group as both displayed a 7-point improvement
in the UPDRS motor off score at 12 months. Although we need to wait
for the publication of these data to have more accurate understanding
reasons for the unexpected failure of the phase II trial, it is possible to
list a number of critical factors that might have contributed to the
negative outcome. The ﬁrst important point to note is that the primary
endpoint of the study was symptomatic relief and not disease
modiﬁcation i.e., indication of neuroprotection, despite the fact that
GDNF's most extensively documented biological effect is neuroprotec-
tion. This somewhat different primary endpoint was probably
preferred due to the experimental design and number of patients
needed to unequivocally prove disease modiﬁcation in PD patients.
Furthermore, some data from the clinical infusion trials have also
indicated symptomatic relief rather than neuroprotective effects of
GDNF; namely the observations after GDNF withdrawal. In one of the
trials, the infusion solution was shifted to saline after 12 months, in a
blinded manner, and the patients were monitored for another year. At
9 to 12 months after cessation of GDNF infusion, the UPDRS scores
returned to baseline and the patients required increased pharma-
cotherapy [121].
A second important point is the fact that the pre-clinical efﬁcacy of
GDNF has been explored almost exclusively on animal models
utilizing neurotoxin based lesions. This means that a critical assump-
tion has been made; namely that neurotoxin based animal models
reproduce the disease mechanism seen in PD patients. The closest
example is probably the MPTP intoxication model in primates, as
humans exposed to MPTP were shown to develop a parkinsonian
syndrome [122,123]. Nevertheless, whether or not the MPTP-induced
parkinsonism cases share a common pathogenic mechanism with
the idiopathic PD cases is not known. Needless to say, none of the
toxin-based models are truly progressive or mimic the major
pathological proﬁles seen in the parkinsonian brain, such as the
formation of Lewy-bodies and neurites [124,125]. In fact, Lo Bianco
and collaborators utilized two rLV vectors to deliver alpha-synuclein
and GDNF to the rodent SN. The rLV-GDNF vector was delivered
2 weeks prior to another rLV vector encoding the human alpha-
synuclein gene and the animals were followed for an additional
6 weeks. In this study they found no signiﬁcant neuroprotective action
of rLV-GDNF compared to the control vector (rLV-LacZ). Although this
experiment did not provide a direct comparison between neuropro-
tective effects of GDNF in a toxic lesion model (e.g., 6-OHDA insult)
and the alpha-synuclein over-expression, it raised concerns about the
validity of toxin-based models for development of neuroprotective
strategies.
Thirdly, the Ceregene trial tested the efﬁcacy of rAAV2-NTN in
advanced PD patients. Although, this choice might have been made
due to restrictions in patient populations that can be recruited to
these experimental trials with invasive and irreversible procedures, it
has a critical impact on the probability of the study to meet its
presumed endpoints. Even for a symptomatic effect, GDNF could be
efﬁcacious only if there is a residual DAergic system present in the
patient's brain that can be reached by the neurotrophic factor. It is this
substrate that is likely to be the main factor affecting the outcome of
the treatment. Thus, advanced PD cases are unlikely to be suitable
candidates for this approach.
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the ﬁeld. Amsterdam Molecular Therapeutics has recently announced
that it had sealed an agreement with Amgen to license GDNF for rAAV
mediated gene therapy in PD [126]. Provided that a carefully planned
study addressing potential shortcomings of the previous trial can be
developed, we are optimistic that successful results can be obtained
with neurotrophic factors in PD.
5. Concluding remarks
The recent progress we have seen in gene therapy for PD
illustrates the rapid advancement of viral vectors as clinical tools for
therapy in the brain. As we tried to elucidate, the currently pursued
strategies are based on several years of research in ﬁelds as diverse
as neurology, pharmacology, molecular biology, virology and ima-
ging. We think that it is only with a thorough understanding of these
ﬁelds that novel, safe and efﬁcient gene therapy strategies canFig. 2. Conceptual ﬂowchart describing a rational decision tree for selection of optimalbecome clinically applicable treatments. It has also become clear that
there will probably be a need for multiple alternative therapeutic
strategies that act via different mechanisms, to provide optimal
treatment to each PD patient who might be suffering from different
causes or severity of disease. In Fig. 2 we provide a summary of our
views and illustrate the different determining points, how different
interpretations of clinical and experimental data can be used to
leverage different approaches to treatment. In the next few years, we
will see the completion the ﬁrst phase I and phase II trials testing
recombinant viral vectors as therapeutic tools in the clinic. Whether
or not the individual trials meet their primary endpoints, the results
from these initial trials are going to give us very precious
information in the reﬁnement of this powerful tool and a substrate
on which better therapeutic products can be designed. It is our
strong belief that in vivo gene transfer techniques will eventually
become an important addition to the therapies offered to PD patients
in the future.gene therapy strategy and a short list of pros and cons for the respective approach.
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